Glucose Fresenius Kabi France (Glucose Monohydrate)

Glucose Fresenius Kabi France is indicated for several therapeutic purposes where intravenous carbohydrate delivery is required.

• Fluid and electrolyte replacement in patients unable to maintain oral intake.
• Caloric supplementation as part of total parenteral nutrition (TPN) regimens.
• Support of blood glucose levels during peri‑operative fasting.
• Management of hypoglycemia when rapid intravenous glucose is needed.
• Provision of an energy source during critical illness or trauma when oral feeding is delayed.

When administered intravenously, glucose solutions can be associated with a range of adverse reactions, most of which are related to the infusion itself or metabolic changes.

Common

• Transient hyperglycemia, especially in patients with impaired insulin response.
• Local irritation or phlebitis at the infusion site.
• Mild electrolyte shifts, such as a temporary decrease in serum potassium.
• Nausea or abdominal discomfort if infused rapidly.

Serious

• Severe hyperglycemia leading to osmotic diuresis or ketoacidosis in susceptible individuals.
• Fluid overload resulting in pulmonary edema, particularly in patients with cardiac or renal dysfunction.
• Hypersensitivity reactions, including rash, urticaria, or anaphylaxis.
• Hyperosmolar hyperglycemic state in patients with uncontrolled diabetes.

Clinicians should evaluate patient-specific factors before initiating therapy with Glucose Fresenius Kabi France to minimize risks.

• Assess baseline blood glucose and adjust infusion rate in diabetic or hyperglycaemic patients.
• Monitor fluid balance and signs of overload in individuals with heart failure, renal impairment, or hepatic disease.
• Use caution in patients with known hypersensitivity to glucose solutions or excipients.
• Verify correct catheter placement and patency to reduce the risk of extravasation.
• Avoid rapid bolus administration unless specifically indicated for acute hypoglycemia.
• Consider electrolyte status, particularly potassium and sodium, before and during infusion.

Glucose solutions may interact with other intravenous medications or affect the pharmacokinetics of concurrently administered drugs.

Avoid

• Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring.
• Simultaneous infusion of potassium chloride in concentrations that may precipitate when mixed with glucose solutions.
• Use with medications that require a strict fluid restriction, such as certain diuretics, without adjusting total volume.

Use with caution

• Concurrent administration of calcium‑containing solutions, which can increase the risk of precipitation.
• Infusion of other hyperosmolar solutions that may exacerbate hyperglycaemia.
• Use in patients receiving vasopressors, as fluid shifts can influence hemodynamic stability.